Updates from Syncona and our portfolio companies
Our CIO, Chris Hollowood, discusses the future of medicine in the wake of coronavirus with Professor David Aanensen (Big Data Institute Oxford), Professor Peter Horby (Oxford University), moderated by John McConnell (The Lancet Infectious Diseases).
Richard Francis discusses why he has taken on the role of CEO at PureSpring Therapeutics, the importance of Syncona’s role (and expertise in the AAV gene therapy field), and the unique opportunity PureSpring has to make a difference to millions of people as it seeks to develop transformational treatments for patients in areas of high unmet need.
Iain McGill introduces Quell Therapeutics, a leader in the new field of T-regulatory cells, and announces their planned expansion to their series A by Syncona making it the largest Series A in the space. Iain discusses Quell’s progress to date and what the financing will enable Quell to achieve
Martin Murphy and Freddie Dear explain why Syncona has expanded Quell’s financing to support the additional pipeline programmes, how they have worked with the Quell team, and their ambition for the company to become a global leader in treating liver transplantation, autoimmune and inflammatory diseases.
Marc Martinez-Llordella, VP Biology at Quell, discusses why liver transplantation is the first programme Quell Therapeutics has selected for entry to the clinic and the advantages of engineered Tregs. Nathalie Belmonte, SVP Research and Translation, discusses Quell’s objective of making a complete cure for liver transplant patients through Tregs, leading to an improvement in patients quality of life and survival. Nathalie also discusses Quell’s new research programmes targeting ALS and Type 1 diabetes
A new Syncona company exploiting the wound healing ability of macrophages to stimulate organ repair following severe injury as a result of chronic disease. Syncona Partners, Ed Hodgkin and Gonzalo Garcia, discuss founding this new company.
Watch Syncona Partner, Dominic Schmidt discuss how we sourced and founded our new kidney gene therapy company, Purespring